• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

426219-53-6 (TAK-700 (salt))

1

Identification

TAK-700 (salt) TAK-700 (salt)
Name TAK-700 (salt)
Formula C28H28N4O7
MW 532.54
CAS No. 426219-53-6
EINECS
Smiles O=C([[email protected]]([[email protected]@H](C(NC1=CC=CC=C1)=O)O)O)O.O=C(NC)C2=CC=C3C=C(C=CC3=C2)C4(CCN5C=NC=C54)O
Synonyms TAK 700 (salt); TAK700 (salt); 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide (2S,3S)-2,3-dihydroxy-4-oxo-4-(phenylamino)butanoate
InChI InChI=1S/C18H17N3O2.C10H11NO5/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21;12-7(8(13)10(15)16)9(14)11-6-4-2-1-3-5-6/h2-5,8-11,23H,6-7H2,1H3,(H,19,22);1-5,7-8,12-13H,(H,11,14)(H,15,16)/t;7-,8-/m.0/s1
2

Introduction

TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase, which is a key enzyme in the production of steroidal hormones. IC50 value: Target: 17,20 lyase In preclinical studies, TAK-700 has been shown to bind to and inhibit the enzyme 17,20 lygase in both the testes and adrenal glands.

Background Information

3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000028745

Storage condition

Solubility

5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
TAK-700 (salt) SWOG Metastatic prostate cancer 2013/3/31 2020/7/1 Phase 3 Clinical
TAK-700 (salt) Radiation Therapy Oncology Group Hormone dependent prostate cancer 2012/5/31 2014/10/1 Phase 3 Clinical
TAK-700 (salt) Millennium Pharmaceuticals Inc Hormone refractory prostate cancer 2010/10/31 2013/6/30 Phase 3 Clinical
TAK-700 (salt) Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung; Swiss Group for Clinical Cancer Research Hormone refractory prostate cancer 2012/9/30 2020/12/31 Phase 3 Clinical
TAK-700 (salt) Millennium Pharmaceuticals Inc; PPD Development (S) Pte Ltd; Takeda Bio Development Center Ltd Hormone refractory prostate cancer 2010/11/30 2013/7/31 Phase 3 Clinical
TAK-700 (salt) - No Development Reported
7

Safety Data of TAK-700 (salt)

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD304(Get quote);10mg/USD464(Get quote);50mg/USD960(Get quote);100mg/USD1800(Get quote) China
10

Related Products

Other Forms of 426219-53-6

Name CAS No Formula MW
TAK-700 (R-form) 752243-39-3 C18H17N3O2 307.35
TAK-700 426219-18-3 C18H17N3O2 307.35

Recommended Compounds in Cytochrome P450

Name CAS No Formula MW
Dafadine-A 1065506-69-5 C23H25N3O3 391.46
VT-464 (racemate) 1375603-36-3 C18H17F4N3O3 399.34
VT-464 1610537-15-9 C18H17F4N3O3 399.34
Isosilybin 72581-71-6 C25H22O10 482.44
Memantine (hydrochloride) 41100-52-1 C12H22ClN 215.76
Clarithromycin 81103-11-9 C38H69NO13 747.95
(+)-Ketoconazole 142128-59-4 C26H28Cl2N4O4 531.43
Ketoconazole 65277-42-1 C26H28Cl2N4O4 531.43
Galangin 548-83-4
Bergapten 484-20-8 C12H8O4 216.19
Naringin 10236-47-2 C27H32O14 580.53
Diosmetin 520-34-3 C16H12O6 300.26
Fenofibrate 49562-28-9 C20H21ClO4 360.83
4-hydroxy-7H-furo[3,2-g]chromen-7-one 486-60-2 C11H6O4 202.16
(R)-Talarozole 870093-23-5 C21H23N5S 377.51
Choline Fenofibrate 856676-23-8 C22H28ClNO5 421.91
Talarozole 201410-53-9 C21H23N5S 377.51
BAL 4815 241479-67-4 C22H17F2N5OS 437.47
Cobicistat 1004316-88-4 C40H53N7O5S2 776.02
Methoxsalen 298-81-7 C12H8O4 216.19

Recommended Compounds in Same Indication

Name CAS No Formula MW
TAK-700 (R-form) 752243-39-3 C18H17N3O2 307.35
Olaparib 763113-22-0 C24H23FN4O3 434.46
KX2-391 897016-82-9 C26H29N3O3 431.53
AT-101 90141-22-3 C30H30O8 518.55
Bicalutamide 90357-06-5 C18H14F4N2O4S 430.37
Enzalutamide 915087-33-1 C21H16F4N4O2S 464.44
Tivozanib 475108-18-0 C22H19ClN4O5 454.86
Orteronel 566939-85-3 C18H17N3O2 307.35
Linsitinib 867160-71-2 C26H23N5O 421.49
Fenretinide 65646-68-6 C26H33NO2 391.55
Leuprolide (Acetate) 74381-53-6 C61H88N16O14 1269.45
Retaspimycin 857402-23-4 C31H45N3O8 587.7
Retaspimycin (Hydrochloride) 857402-63-2 C31H46ClN3O8 624.17
(S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide 859212-16-1 C30H31F3N8O 576.62
AT13387 912999-49-6 C24H31N3O3 409.52
Tasquinimod 254964-60-8 C20H17F3N2O4 406.36
TAK-700 426219-18-3 C18H17N3O2 307.35
TOK-001 851983-85-2 C26H32N2O 388.55
Cabozantinib 849217-68-1 C28H24FN3O5 501.51
Odanacatib 603139-19-1 C25H27F4N3O3S 525.56
11

Route of Synthesis

12

References

13

More Information

TAK-700 (salt)

Tags: buy 426219-53-6 IC50 | 426219-53-6 price | 426219-53-6 cost | 426219-53-6 solubility | 426219-53-6 purchase | 426219-53-6 manufacturer | 426219-53-6 research buy | 426219-53-6 order | 426219-53-6 MSDS | 426219-53-6 chemical structure | 426219-53-6 Storage condition | 426219-53-6 molecular weight | 426219-53-6 mw | 426219-53-6 datasheet | 426219-53-6 supplier | 426219-53-6 cell line | 426219-53-6 NMR | 426219-53-6 MS | 426219-53-6 IR | 426219-53-6 solubility | 426219-53-6 Safe information | 426219-53-6 Qc and Spectral Information | 426219-53-6 Clinical Information | 426219-53-6 Clinical Trial | 426219-53-6 Route of Synthesis | 426219-53-6 storage condition | 426219-53-6 diseases and conditions | 426219-53-6 flash point | 426219-53-6 boiling point | 426219-53-6 melting point | 426219-53-6 storage condition | 426219-53-6 brand